PGR and breast carcinoma: We also contrasted the expression of both β-CATENIN [i.e. non-phospho (active) β-catenin (SER33/37/Thr41) vs. a pan-β-catenin-antibody] and AXIN2 in TNBC with other breast cancer subtypes (ER+, PR+, HER2+ and TP+; Supporting Information Fig S8A–C).